Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors

Androgen-independent recurrence is the major limit of androgen ablation therapy for prostate cancer. Identification of alternative pathways promoting prostate tumor growth is thus needed. Stat5 has been recently shown to promote human prostate cancer cell survival/proliferation and to be associated with early prostate cancer recurrence. Stat5 is the main signaling pathway triggered by prolactin (PRL), a growth factor whose local production is also increased in high-grade prostate cancers. The first aim of this study was to use prostate-specific PRL transgenic mice to address the mechanisms by which local PRL induces prostate tumorogenesis. We report that (i) Stat5 is the major signaling cascade triggered by local PRL in the mouse dorsal prostate, (ii) this model recapitulates prostate tumorogenesis from precancer lesions to invasive carcinoma, and (iii) tumorogenesis involves dramatic accumulation and abnormal spreading of p63-positive basal cells, and of stem cell antigen-1–positive cells identified as a stem/progenitor-like subpopulation. Because basal epithelial stem cells are proposed to serve as tumor-initiating cells, we challenged the relevance of local PRL as a previously unexplored therapeutic target. Using a double-transgenic approach, we show that Δ1–9-G129R-hPRL, a competitive PRL-receptor antagonist, prevented early stages of prostate tumorogenesis by reducing or inhibiting Stat5 activation, cell proliferation, abnormal basal-cell pattern, and frequency or grade of intraepithelial neoplasia. This study identifies PRL receptor/Stat5 as a unique pathway, initiating prostate tumorogenesis by altering basal-/stem-like cell subpopulations, and strongly supports the importance of further developing strategies to target locally overexpressed PRL in human prostate cancer.

[1]  S. Memarzadeh,et al.  Basal epithelial stem cells are efficient targets for prostate cancer initiation , 2010, Proceedings of the National Academy of Sciences.

[2]  E. Crawford,et al.  Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. , 2009, Urology.

[3]  P. Kelly,et al.  Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors , 2008, Proceedings of the National Academy of Sciences.

[4]  W. Gerald,et al.  Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. , 2008, The Journal of clinical investigation.

[5]  N. Maitland,et al.  Prostate cancer stem cells: a new target for therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Leiby,et al.  Transcription Factor Signal Transducer and Activator of Transcription 5 Promotes Growth of Human Prostate Cancer Cells In vivo , 2008, Clinical Cancer Research.

[7]  O. Witte,et al.  Stem cells in prostate cancer initiation and progression. , 2007, The Journal of clinical investigation.

[8]  M. Nevalainen,et al.  Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. , 2007, Endocrinology.

[9]  M. LeBaron,et al.  In vivo response-based identification of direct hormone target cell populations using high-density tissue arrays. , 2007, Endocrinology.

[10]  Shunyou Wang,et al.  Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[11]  E. Gehan,et al.  Activation of Signal Transducer and Activator of Transcription-5 in Prostate Cancer Predicts Early Recurrence , 2005, Clinical Cancer Research.

[12]  D. Moscatelli,et al.  Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[13]  O. Witte,et al.  The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  P. Kelly,et al.  0163-769X/05/$20.00/0 Endocrine Reviews 26(3):400–422 Printed in U.S.A. Copyright © 2005 by The Endocrine Society doi: 10.1210/er.2004-0016 Development and Potential Clinical Uses of Human Prolactin Receptor Antagonists , 2022 .

[15]  C. Morrissey,et al.  Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. , 2005, Clinical science.

[16]  J. Xie,et al.  Activation of Signal Transducer and Activator of Transcription 5 in Human Prostate Cancer Is Associated with High Histological Grade , 2004, Cancer Research.

[17]  M. Rubin,et al.  Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee , 2004, Cancer Research.

[18]  G. Norstedt,et al.  Gene expression analysis of prostate hyperplasia in mice overexpressing the prolactin gene specifically in the prostate. , 2003, Endocrinology.

[19]  J. Martial,et al.  Development of Pure Prolactin Receptor Antagonists* , 2003, Journal of Biological Chemistry.

[20]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[21]  P. Kelly,et al.  Prostate development and carcinogenesis in prolactin receptor knockout mice. , 2003, Endocrinology.

[22]  Todd R. Golub,et al.  Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Ormandy,et al.  Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. , 2003, Endocrinology.

[24]  Jose J. Galvez,et al.  Prostatic intraepithelial neoplasia in genetically engineered mice. , 2002, The American journal of pathology.

[25]  J. Haseman,et al.  Spontaneous Lesions in Control B6C3F1 Mice and Recommended Sectioning of Male Accessory Sex Organs , 2002, Toxicologic pathology.

[26]  M. Nevalainen,et al.  PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro. , 2002, Endocrinology.

[27]  R Montironi,et al.  p63 is a prostate basal cell marker and is required for prostate development. , 2000, The American journal of pathology.

[28]  P. Kelly,et al.  Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. , 1998, Endocrine reviews.

[29]  M. Nevalainen,et al.  Prolactin and prolactin receptors are expressed and functioning in human prostate. , 1997, The Journal of clinical investigation.